Difference between revisions of "Team:BIT/nb"
| Line 81: | Line 81: | ||
<p><span class="label-warning"><font size=4><font color=black> March: </font> </font></span></p> | <p><span class="label-warning"><font size=4><font color=black> March: </font> </font></span></p> | ||
</span><p> <br> | </span><p> <br> | ||
| − | i. | + | i. Week 1-2(2017.03.04-2017.03.17) |
<br> | <br> | ||
| − | After discussion, the main goal of our project was to detect cancer of the liver by using small molecule | + | |
| + | After discussion, the main goal of our project was to detect cancer of the liver by using small molecule | ||
<br> | <br> | ||
| − | ii. | + | ii. Week 3(2017.03.18-2017.03.24) |
<br> | <br> | ||
| − | After reviewing the literature, we chose lysine as our small molecule and chose lysine-deficient | + | |
| + | After reviewing the literature, we chose lysine as our small molecule and chose lysine-deficient E.coli as our bacteria. | ||
<br> | <br> | ||
| − | + | iii. week4(2017.03.25-2017.03.31)</span><br> | |
| − | iii. | + | |
| − | + | We chose our main experimental method.<br> | |
| − | + | ||
| − | + | </p> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | <br> | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
Revision as of 20:39, 31 October 2017
Journal
March:
i. Week 1-2(2017.03.04-2017.03.17)
After discussion, the main goal of our project was to detect cancer of the liver by using small molecule
ii. Week 3(2017.03.18-2017.03.24)
After reviewing the literature, we chose lysine as our small molecule and chose lysine-deficient E.coli as our bacteria.
iii. week4(2017.03.25-2017.03.31)
We chose our main experimental method.
April:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
May:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
June:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
July:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
August:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
September:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
October:
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
Hire Us!
Facilis ipsum reprehenderit nemo molestias. Aut cum mollitia reprehenderit. Eos cumque dicta adipisci architecto culpa amet.
